Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Agfa Healthcare
ElsMed

Molecular Imaging Tracers Help Determine Brain Metastases Treatment Strategies

By Medimaging International staff writers
Posted on 17 Dec 2013
Imaging with the molecular imaging tracer 18F-FDOPA (L-3,4-dihydroxy-6-[18F]fluoro-phenylalanine) can help differentiate radiation-induced lesions from new tumor growth in patients who have been treated with radiotherapy for brain metastases, according to new research.

Using this amino acid tracer, researchers discovered that physicians could effectively differentiate the two types of lesions 83% of the time. Progression-free survival could also be predicted through evaluating the 18F-FDOPA imaging findings.

Brain metastases occur in 20%–40% of all cancer patients, especially in those with melanoma, non-small-cell lung cancer, and breast cancer. They account for 170,000 new cases yearly in the United States alone, and prognosis is poor. Treatment for brain metastases usually includes a combination of surgery, radiation treatment, and chemotherapy.

“Histopathological changes in neural tissue treated with radiation could trigger clinical and imaging manifestations which are very similar to those caused by tumor growth,” said Karlo J. Lizarraga, MD, MS, from the department of neurology, Miller School of Medicine, University of Miami (FL, USA), and lead author of the study. “The challenge is then to differentiate whether these manifestations are due to radiation or to tumor progression or recurrence. Accurate and timely distinction between these two possibilities can significantly affect patient care, and outcome for treatment modalities are completely different for each case.”

In the retrospective study, published ahead of print October 28, 2013, and slated for the January 1, 2014, issue of the Journal of Nuclear Medicine, researchers analyzed images from 32 patients who had 83 earlier irradiated brain metastases and who underwent 18F-FDOPA positron emission tomography (PET). The studies were analyzed both semi-quantitatively and visually to determine whether lesions were caused by radiation injury or were recurrent or progressive brain metastases. Results were verified by histopathologic analysis or clinical follow-up. The prognostic ability of 18F-FDOPA in predicting progression-free survival and overall survival was also studied with the Kaplan-Meier and Cox regression techniques.

The best overall accuracy for differentiating between the two types of lesions was achieved using visual scoring, which had a sensitivity of 81.3%, a specificity of 84.3%, and an overall accuracy of 83.1%. The semi-quantitative analysis resulted in a sensitivity of 81.3%, a specificity of 72.5% and an overall accuracy of 75.9%.

Researchers also discovered that evaluations with 18F-FDOPA PET was highly prognostic of progression-free survival, as lesions with a negative PET result had a mean time to progression that was 4.6 times longer than lesions with positive 18F-FDOPA PET findings. Moreover, a trend toward predicting overall survival was also seen.

18F-FDOPA PET imaging is currently available in few centers. The longer physical half-life of 18F-FDOPA, when compared to other amino acid tracers, gives it the advantage of potential automated production and transport to PET centers for widespread use,” noted Dr. Lizarraga.

Related Links:

Miller School of Medicine, University of Miami



Channels

Radiography

view channel
Image: The Siemens Healthcare Somatom Force CT system (Photo courtesy of Siemens Healthcare).

New CT Scanning Technology Is Faster, Uses Less Radiation, and Easier on the Kidneys

Patients who must undergo computed tomography (CT) scanning now have a new option for screening that is extremely fast, uses less radiation, and is safer for the kidneys. With US Food and Administration... Read more

MRI

view channel
Image: In a preterm infant’s brain, an MRI scan can reveal abnormalities that were undetected by previous methods. The scans on the left show normal gray matter, while those on the right show abnormal gray matter (Photo courtesy of Washington University in St. Louis).

MRI Tracks Infant Brain Growth in First Months of Life

For the first time, researchers have used magnetic resonance imaging (MRI) of the newborn brain to calculate the volume of multiple brain regions and to map out regional growth trajectories during the... Read more

Ultrasound

view channel
Image: UAMS researcher William Culp, MD, (right), and Doug Wilson of UALR (left) have developed a device to treat stroke (Photo courtesy of UAMS/UALR Office of Communications).

Clot-Buster Ultrasound Device May Become Best Treatment Option for Stroke Patients

A new device is being developed to treat stroke more effectively. The new technology fits on the head similar to a halo and delivers therapy to rapidly bust clots that cause stroke. The device was developed... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.